By: Editorial Staff
Date: May 08, 2026
In the quiet moments of a medical diagnosis, time often seems to fracture. For Susan Peluso, that rupture occurred in March 2023. At 54 years old, Peluso was a picture of health—an active woman whose life was defined by her daily routines and future plans. That changed in an instant with the delivery of four words: "high-grade serous ovarian cancer."
Her story is not just a personal chronicle of survival; it is a vital reminder of the insidious nature of ovarian cancer, a disease often called the "silent killer" due to its vague early symptoms and the lack of reliable screening tools. As we mark World Ovarian Cancer Day, Peluso’s journey serves as a poignant testament to the resilience of the human spirit and the critical importance of patient advocacy in the face of a stage 4B diagnosis.
The Anatomy of a Diagnosis: A Chronological Timeline
The trajectory of Peluso’s battle illustrates the brutal pace at which high-grade serous ovarian cancer can progress.
The Onset (Early 2023)
Prior to her diagnosis, Peluso experienced symptoms that were easily dismissed. Sharp rectal pain, which she initially believed to be simple muscle spasms, was, in reality, the early warning sign of a malignancy that had already begun to take root.
The Surgical Intervention (May 2023)
By May, the diagnosis was confirmed as stage 4B, indicating that the cancer had metastasized to multiple organs. Peluso underwent an aggressive course of action: a complete hysterectomy combined with debulking surgery. This procedure is designed to remove as much of the tumor mass as possible to improve the efficacy of subsequent systemic treatments.
The Treatment Regimen (2023–2025)
Following surgery, Peluso entered a grueling cycle of medical intervention. She completed six rounds of chemotherapy, followed by a maintenance regimen of 21 cycles of Avastin (bevacizumab), a targeted therapy that inhibits the growth of new blood vessels that tumors need to survive. This treatment lasted until February 2025.
The Window of NED (2025–2026)
For 26 months post-chemotherapy, Peluso lived in the "fragile, beautiful space" of NED—No Evidence of Disease. It was a time of cautious optimism, where the shadow of cancer receded just enough to allow her to reclaim her identity outside of the clinical setting.
The Recurrence (2026)
In January 2026, the fragility of that hope was tested. A routine CT scan and liver MRI revealed that the disease had returned. By March 2, Peluso was back in the operating room for a second debulking surgery, and on April 8, she began a new round of chemotherapy, once again stepping back into the fray.
The Silent Crisis: Understanding Ovarian Cancer
To understand why Peluso’s story is so significant, one must understand the landscape of ovarian cancer. According to the American Cancer Society and other global oncology bodies, ovarian cancer is the fifth leading cause of cancer death among women.
The Diagnostic Challenge
The primary challenge in managing this disease is that it is frequently diagnosed in late stages. Unlike cervical or breast cancer, there is no standard, reliable screening test for ovarian cancer in the general population. Symptoms—such as abdominal bloating, pelvic pain, difficulty eating, or frequent urination—are often attributed to less serious gastrointestinal issues, leading to significant delays in diagnosis.
The Role of Advocacy and Organizations
Peluso credits much of her mental and emotional stamina to organizations like Sharsheret. Sharsheret, a national non-profit organization, provides essential support to Jewish women and their families facing breast and ovarian cancer.
"What carries me through is not just treatment, but the people and organizations like Sharsheret who lift me up and remind me who I am beyond this diagnosis," Peluso notes. These support networks are crucial in filling the gaps that clinical medicine often leaves behind: the psychological, emotional, and social toll of living with a chronic, life-threatening condition.
Supporting Data and Medical Implications
Medical experts emphasize that the treatment of advanced-stage ovarian cancer is shifting toward a more personalized approach. The use of PARP inhibitors and other targeted therapies has changed the landscape for many patients, extending the "progression-free survival" (PFS) periods that Peluso navigated.
However, the reality of recurrence remains a major hurdle. Statistics suggest that a high percentage of patients with advanced ovarian cancer will experience a recurrence within the first few years of their initial treatment. This reality underscores the need for:
- Earlier Detection Research: Continued investment in biomarkers and diagnostic imaging that can identify the disease in its earliest stages.
- Patient-Centered Care: A multidisciplinary approach that includes not just oncologists and surgeons, but also mental health professionals, nutritionists, and peer support groups.
- Genetic Counseling: Given that many ovarian cancers are linked to BRCA1 and BRCA2 gene mutations, genetic testing is becoming a standard of care to help tailor treatment plans and inform family members of their own risk levels.
The Advocacy Call: Listen to Your Body
The core message of Peluso’s story is an urgent call to action for all women: Advocacy begins with self-awareness.
"If sharing my story does anything, I hope it encourages someone to listen to their body, ask questions, and advocate for answers," Peluso says. When a patient feels that something is wrong—even if the symptoms are ambiguous—they must push for comprehensive diagnostic testing. This might mean seeking a second opinion, requesting specialized imaging, or consulting with a gynecologic oncologist rather than a general practitioner.
The medical establishment has a role to play as well. Physicians are increasingly being urged to consider ovarian cancer as a potential diagnosis when patients present with persistent, unexplained pelvic or abdominal symptoms, particularly in women over the age of 50.
Implications for the Future of Care
As Peluso continues her second round of chemotherapy, her narrative challenges the medical community to look beyond the numbers. Her journey represents a "living with cancer" model, where the objective is not just to eradicate the disease, but to maintain quality of life, purpose, and hope.
The implications for the future are clear:
- Technological Advancement: The rise of liquid biopsies and improved genomic sequencing will likely pave the way for earlier intervention.
- Supportive Care Integration: Organizations like Sharsheret demonstrate that holistic support—community, counseling, and peer connection—is a medical necessity, not a luxury.
- Empowered Patients: The model of the "passive patient" is being replaced by the "empowered partner," where the patient works in tandem with their clinical team to navigate treatment paths that align with their personal values and life goals.
Conclusion: Still Here
World Ovarian Cancer Day is a day of awareness, but for many, it is also a day of reflection. For Susan Peluso, it is a day of defiance.
"This is not the chapter I wanted—but it is the one I’m living," she reflects. By sharing her vulnerability, she has transformed her personal ordeal into a public beacon for others. Her story reinforces that while the battle against ovarian cancer is ongoing, the fight is never fought in isolation.
As we look toward the future, the goal remains twofold: to improve the outcomes for those facing this diagnosis through scientific innovation, and to ensure that every woman feels seen, heard, and supported, just as Peluso has found through her own journey.
On this World Ovarian Cancer Day, we honor those who have fought, those who continue to fight, and the indomitable hope that drives the medical community to find a cure. Susan Peluso is still here. She is still fighting. And, in the face of every medical challenge, she remains hopeful—a reminder to us all that even in the darkest chapters, the human spirit is a force to be reckoned with.
About the Author
